A Phase 3 interventional study of GWP42003-P in Infantile Spasms, sponsored by Jazz Pharmaceuticals. Completed at 8 sites in 2 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2022-09-02.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Spasms, Infantile with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Spasms, Infantile · United States.
Among the 22 studies in Spasms, Infantile with a site in United States, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 9th registered.
47 studies on the registry are indexed under Spasms, Infantile; 8 are open to participants now.
Browse Spasms, Infantile studies →2 of the 22 studies in Spasms, Infantile with a site in United States are open now. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 2 mo–18 mo
Children's Hospital of Orange County · Sites in United States
Ages 12 mo–36 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Spasms, Infantile studies recruiting now, none set no upper age limit and 7 stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 1 Month to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 40 across 33 interventional studies indexed under Spasms, Infantile.
Median enrollment 10 across the 18 interventional studies, 72 across the 4 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 22 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 3 studies filed under Spasms, Infantile — fewer than ten, so there is no comparison to draw.
2 of the studies in Spasms, Infantile with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05064878Phase 3Zogenix, Inc.A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. | 2027-11-08 |
| NCT04289467Children's Hospital of Orange CountyTreatment of Refractory Infantile Spasms With Fenfluramine | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Spasms, Infantile with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The pilot phase only will be described in this record. 2 cohorts of 5 participants will be enrolled sequentially. All participants will receive GWP42003-P.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
Drug: GWP42003-P
Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Also known as: CBD, Cannabidiol
Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)
TEAEs are defined as all adverse events not present prior to the first investigational medicinal product (IMP) or placebo administration or any event already present that worsened in severity or frequency following IMP.
Time frame: From signing of informed consent up to Day 15
Number of Participants With Any Low or High Hematology Laboratory Parameter Value
Time frame: Day 4 and Day 15
Number of Participants With Any Low or High Biochemistry Laboratory Parameter Value
Time frame: Day 4 and Day 15
Number of Participant With Any Clinically Relevant Urinalysis Parameter Value
Clinical relevance was determined by the investigator.
Time frame: Day 4 and Day 15
Number of Participants With Clinically Significant Electrocardiogram Findings
Clinical significance was determined by the investigator.
Time frame: From signing of informed consent up to Day 15
Number of Participants With Clinically Significant Physical Examination Findings
Clinical significance was determined by the investigator.
Time frame: From signing of informed consent up to Day 15
Number of Participants With Clinically Significant Vital Sign Findings
Clinical significance was determined by the investigator.
Time frame: From signing of informed consent up to Day 15
Number of Participants Free of Clinical Spasms
Clinical spasms were determined by video-electroencephalography (VEEG) for at least 8 hours and up to 24 hours.
Time frame: Day 15
Percentage of Participants Free of Clinical Spasms
Clinical spasms were determined by VEEG for at least 8 hours and up to 24 hours.
Time frame: Day 15
Number of Participants With Resolution of Hypsarrhythmia
Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.
Time frame: Day 15
Percentage of Participants With Resolution of Hypsarrhythmia
Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.
Time frame: Day 15
Number of Participants Experiencing Spasms and Seizures by Subtype
Caregivers recorded the participant's spasms and seizures by category in a daily diary. Subtypes of spasms and seizures included: clonic, tonic-clonic, myoclonic, focal, and absence.
Time frame: Day 4 and Day 15
Average Time to Cessation of Spasms
Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase (NCT02954887) for up to 1 year.
Time frame: Day 1 to start of Open-label Extension (OLE) Phase
Caregiver Clinical Global Impression of Change (CGIC)
The CGIC is a single-question assessment completed by the caregiver. The question assessed the status of the participant's condition since treatment start. The caregiver provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).
Time frame: Day 15
Physician Global Impression of Change (PGIC)
The PGIC is a single-question assessment completed by the investigator. The question assesses the status of the participant's condition since treatment start. The investigator provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).
Time frame: Day 15
Number of Responders
A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.
Time frame: Baseline to Day 15
Percentage of Responders
A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.
Time frame: Baseline to Day 15
Participants were screened to assess their eligibility to enter the trial within 7 days prior to the first dose administration.
| Milestone | Cohort 1: GWP42003-P OS | Cohort 2: GWP42003-P OS |
|---|---|---|
| Started | 5 | 4 |
| Completed | 5 | 4 |
| Not completed | 0 | 0 |
TEAEs are defined as all adverse events not present prior to the first investigational medicinal product (IMP) or placebo administration or any event already present that worsened in severity or frequency following IMP.
| Participants | GWP42003-P OS |
|---|---|
| Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs) | 6 |
| Participants | GWP42003-P OS |
|---|---|
| Day 4, Low | 4 |
| Day 4, High | 4 |
| Day 15, Low | 1 |
| Day 15, High | 3 |
| Participants | GWP42003-P OS |
|---|---|
| Day 4, Low | 7 |
| Day 4, High | 5 |
| Day 15, Low | 5 |
| Day 15, High | 7 |
Clinical relevance was determined by the investigator.
| Participants | GWP42003-P OS |
|---|---|
| Day 4 | 0 |
| Day 15 | 0 |
Clinical significance was determined by the investigator.
| Participants | GWP42003-P OS |
|---|---|
| Number of Participants With Clinically Significant Electrocardiogram Findings | 0 |
Clinical significance was determined by the investigator.
| Participants | GWP42003-P OS |
|---|---|
| Number of Participants With Clinically Significant Physical Examination Findings | 0 |
Clinical significance was determined by the investigator.
| Participants | GWP42003-P OS |
|---|---|
| Number of Participants With Clinically Significant Vital Sign Findings | 0 |
Clinical spasms were determined by video-electroencephalography (VEEG) for at least 8 hours and up to 24 hours.
| Participants | GWP42003-P OS |
|---|---|
| Number of Participants Free of Clinical Spasms | 0 |
Clinical spasms were determined by VEEG for at least 8 hours and up to 24 hours.
| percentage of participants | GWP42003-P OS |
|---|---|
| Percentage of Participants Free of Clinical Spasms | 0 |
Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.
| Participants | GWP42003-P OS |
|---|---|
| Number of Participants With Resolution of Hypsarrhythmia | 0 |
Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.
| percentage of participants | GWP42003-P OS |
|---|---|
| Percentage of Participants With Resolution of Hypsarrhythmia | 0 |
Caregivers recorded the participant's spasms and seizures by category in a daily diary. Subtypes of spasms and seizures included: clonic, tonic-clonic, myoclonic, focal, and absence.
| Participants | GWP42003-P OS |
|---|---|
| Day 4, Clonic | 0 |
| Day 4, Tonic-Clonic | 1 |
| Day 4, Atonic | 0 |
| Day 4, Myoclonic | 0 |
| Day 4, Focal | 1 |
| Day 4, Absence | 0 |
| Day 4, Not Done | 0 |
| Day 15, Clonic | 0 |
| Day 15, Tonic-Clonic | 0 |
| Day 15, Atonic | 0 |
| Day 15, Myoclonic | 0 |
| Day 15, Focal | 2 |
| Day 15, Absence | 0 |
| Day 15, Not Done | 0 |
Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase (NCT02954887) for up to 1 year.
No measurements were reported for this outcome.
The CGIC is a single-question assessment completed by the caregiver. The question assessed the status of the participant's condition since treatment start. The caregiver provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).
| participants | GWP42003-P OS |
|---|---|
| Very Much Improved | 1 |
| Much Improved | 0 |
| Slightly Improved | 7 |
| No Change | 1 |
| Slightly Worse | 0 |
| Much Worse | 0 |
| Very Much Worse | 0 |
| Not Done | 0 |
The PGIC is a single-question assessment completed by the investigator. The question assesses the status of the participant's condition since treatment start. The investigator provided a rating on a 7-point scale from 1 (very much improved) to 7 (very much worse).
| participants | GWP42003-P OS |
|---|---|
| Very Much Improved | 0 |
| Much Improved | 1 |
| Slightly Improved | 5 |
| No Change | 3 |
| Slightly Worse | 0 |
| Much Worse | 0 |
| Very Much Worse | 0 |
| Not Done | 0 |
A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.
| responders | Cohort 1: GWP42003-P OS | Cohort 2: GWP42003-P OS |
|---|---|---|
| Number of Responders | 0 | 0 |
A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Testing for responders was conducted by VEEG for at least 8 hours and up to 24 hours.
| responders | Cohort 1: GWP42003-P OS | Cohort 2: GWP42003-P OS |
|---|---|---|
| Percentage of Responders | 0 | 0 |
Collected over From signing of informed consent up to Day 15. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P OS | 0/9 (0%) | 1/9 (11.1%) | 5/9 (55.6%) |
| Event | GWP42003-P OS |
|---|---|
| Status epilepticusNervous system disorders | 1/9 |
| Event | GWP42003-P OS |
|---|---|
| DiarrhoeaGastrointestinal disorders | 2/9 |
| Upper respiratory tract infectionInfections and infestations | 2/9 |
| Application site erosionGeneral disorders | 1/9 |
| IrritabilityPsychiatric disorders | 1/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/9 |
| SomnolenceNervous system disorders | 1/9 |
| ConstipationGastrointestinal disorders | 1/9 |
| VomitingGastrointestinal disorders | 1/9 |
| HaematuriaRenal and urinary disorders | 1/9 |
| Increased appetiteMetabolism and nutrition disorders | 1/9 |
Safety Analysis Set
| Age, Continuous(years) | GWP42003-P OS |
|---|---|
| Mean | 12.2 ± 5.56 |
| Sex: Female, Male(Participants) | GWP42003-P OS |
|---|---|
| Female | 6 |
| Male | 3 |
| Race (NIH/OMB)(Participants) | GWP42003-P OS |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in May 2018, 12 months.
Results were first posted in Jul 2020, 2 years 2 months after primary completion. A results delay was requested in Dec 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol